TLDR
- Biogen stock hit a 52-week high of $219.94, up 57% over the past year
- Q2 revenue came in at $2.74 billion, beating analyst expectations of $2.46 billion
- EPS of $3.60 beat the consensus estimate of $2.94
- Biogen raised its full-year 2026 revenue outlook to a mid-single-digit increase
- BlackRock bought 15.98 million Biogen stock units valued at approximately $3.45 billion
Biogen (BIIB) stock hit a 52-week high of $219.94 on Tuesday, up 57% over the past year. The stock opened at $212.55 on Wednesday and has a 52-week low of $131.52.
The move comes after a strong Q2 earnings report and a massive new position taken by BlackRock.
BlackRock bought 15.98 million units of Biogen stock in Q2, valued at around $3.45 billion. That gives the asset manager roughly 10.82% ownership of the company.
Several other institutional investors also added to their positions. Empowered Funds lifted its stake by 64.9%, Focus Partners Wealth increased its position by 172.2%, and Cerity Partners boosted its stake by 15.3%. In total, institutional investors and hedge funds now own 87.93% of BIIB.
Biogen posted Q2 revenue of $2.74 billion, beating analyst expectations of $2.46 billion. EPS came in at $3.60, well ahead of the consensus estimate of $2.94.
Full-Year Outlook Raised
Off the back of those results, Biogen raised its full-year 2026 revenue guidance from a mid-single-digit decline to a mid-single-digit increase. That’s a meaningful swing in direction, driven by newer products and a growing rare-disease portfolio.
Full-year EPS guidance was set at $12.00 to $13.00. Analysts currently forecast $12.39 EPS for the year.
The stock trades at a P/E ratio of 37.62 and has a market cap of $31.40 billion. Its 50-day moving average sits at $204.36 and its 200-day moving average at $193.76.
Analyst Targets
Wall Street has responded positively to recent results. Canaccord Genuity raised its price target to $248 and kept a Buy rating. Guggenheim reiterated Buy with a $280 target. Oppenheimer maintained an Outperform rating with a $300 price target. H.C. Wainwright raised its target to $251.
Not everyone is as bullish. Barclays raised its target from $185 to $200 but kept an Equal Weight rating. JPMorgan lifted its target from $175 to $185 with a Neutral rating.
The consensus across analysts currently stands at a “Moderate Buy” with an average price target of $227.07. Of the analysts covering the stock, 18 have a Buy rating, 13 have a Hold, one has a Strong Buy, and one has a Sell.
Biogen is also preparing to release results from its Phase 3 TOPAZ-1 and TOPAZ-2 lupus drug trials. The InvestingPro platform lists “high return over the last year” as a key metric and flags the stock as appearing undervalued at current levels.
The stock’s debt-to-equity ratio stands at 0.39, with a current ratio of 1.87 and a beta of just 0.17.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
